Erdosteine effectively inhibits lipopolysaccharide (LPS)-induced NF-κB activation, demonstrating its anti-inflammatory capabilities[1].[2]. Additionally, Erdosteine is recognized for its muco-modulatory, antibacterial, anti-inflammatory, and antioxidant effects[3].
体外研究
It is an oral mucolytic agent widely used as an expectorant in treating chronic respiratory diseases. Specifically, Erdosteine inhibits NF-κB activation in LPS-stimulated mouse macrophages, though it does not affect LPS-induced phosphorylation of the Akt and MAPK pathways. To assess its toxicity, cell viability was tested and showed that treatments with Erdosteine at concentrations of 1, 10, or 100 μg/mL did not produce detectable cytotoxic effects. In experiments involving RAW 264.7 cells, treatment with 1 μg/mL LPS induced IκBα degradation, which was most pronounced at 10 minutes. These cells were also pretreated with Erdosteine for 6 hours before being stimulated with LPS for 10 minutes[1].
South Africa
... 展开 >> Emavundleni Desmond Tutu HIV Centre CRS
Cape Town, Western Cape, South Africa, 7750
Aurum Institute for Health Research
Klerksdorp, South Africa, 2570
Perinatal HIV Research Unit
Soweto, South Africa, 2013 收起 <<
South Africa
... 展开 >> Emavundleni Desmond Tutu HIV Centre CRS
Cape Town, Western Cape, South Africa, 7750
Aurum Institute for Health Research
Klerksdorp, South Africa, 2570
Perinatal HIV Research Unit
Soweto, South Africa, 2013 收起 <<
Thailand
... 展开 >> Royal Thai Army Clinical Research Center, AFRIMS
Bangkok, Thailand, 10400
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand, 10400
Research Institute for Health Sciences (RIHES), Chiang Mai University
Chiang Mai, Thailand, 50202 收起 <<
搜索
